THE ALLIANCE | How pharma companies & physicians joined forces

Overview | Urology | Dermatology | Hair transplant surgery | Endocrinology | Merck & GSK | Study groups | References | People index

Study groups

Lists only include individuals highlighted in this special section. Co-authors of papers published on behalf of study groups were assumed to be study group members. See also a summary of clinical trials.

Merck

Finasteride Male Pattern Hair Loss Study Group
Treatment for male pattern hair loss

• Julianne Imperato-McGinley, MD
• Elise Olsen, MD
• Vera H. Price, MD
• Roger Rittmaster, MD
• Janet Roberts, MD
• Jerry Shapiro, MD
• Dow Stough, MD
• David Whiting, MD
• Merck
  • Keith Kaufman, MD
  • Elizabeth Round, MD
  • Joanne Waldstreicher, MD
• Papers: Kaufman 1998, Roberts 1999, Drake 1999, Finasteride Male Pattern Hair Loss Study Group 2002, Shapiro 2003, Price 2006, Kaufman 2008a, Kaufman 2008b

Finasteride Study Group
Treatment for benign prostatic hyperplasia

• Gerald Andriole, MD
• Julianne Imperato-McGinley, MD
• John McConnell, MD
• Roger Rittmaster, MD
• Patrick Walsh, MD
• Merck
  • Glenn Gormley, MD, PhD
  • Elizabeth Stoner, MD
• Papers: Gormley 1992, Guess 1993, Stoner 1994, Finasteride Study Group 1993, Stoner 1994, Hudson 1999, Lowe 2003

The Finasteride 6-year Study Group supported a five-year extension beyond the first year of the Phase III trial. The group consisted of the Finasteride North American Study Investigators, including all individuals listed above, and the Finasteride International Study Investigators, as specified in Lowe 2003.

MTOPS: Medical Therapy of Prostatic Symptoms Research Group
Long-term effect of doxazosin, finasteride & combination therapy on progression of benign prostatic hyperplasia
Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (US)

• John McConnell, MD, PhD – Steering committee chairman and investigator, University of Texas Southwestern Medical Center, Dallas
• Stephen Kaplan, MD – Principal Investigator, New York Presbyterian Hospital, New York
• Claus Roehrborn, MD – Principal Investigator, University of Texas Southwestern Medical Center, Dallas
• Norman Lepor, MD – Investigator, New York University School of Medicine, New York
• Kevin McVary, MD – Principal Investigator, Northwestern University, Chicago
• Gerald Andriole, MD – Principal Investigator, Washington University, St. Louis
• Merck – ex officio members of the steering committee
  • Elizabeth Round, MD
  • Glenn Gormley, MD
• Papers: McConnell 1998, Kaplan 2016

PLESS: Finasteride Long-Term Efficacy and Safety Study Group

• Gerald Andriole, MD
• Stephen Kaplan, MD
• John McConnell, MD
• J. Curtis Nickel, MD
• Claus Roehrborn, MD
• Patrick Walsh, MD
• Merck
  • Elizabeth Stoner, MD
  • Joanne Waldstreicher, MD
• Papers: Andriole 1998, Bruskewitz 1999, Roehrborn 1999, Yang 1999, Kaplan 2000, Roehrborn 2000, Wessells 2003, Roehrborn 2004

PROSPECT: PROscar Safety Plus Efficacy Canadian Two-year Study Group

• J. Curtis Nickel, MD
• Paper: Nickel 1996

PROWESS Study Group
Long-term effects of finasteride in patients with benign prostatic hyperplasia 

This international study group did not include any individuals highlighted in this section. The resulting paper was Marberger 1998.

Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
Safety and efficacy of terazosin, finasteride, and the combination of both drugs

• Norman Lepor, MD
• Papers: Lepor 1996, Lepor 1998

GlaxoSmithKline

ARIA Study Investigators
ARIA3001 (US), ARIA3002 (US) & ARIA3003 (19 countries)
Dutasteride as a treatment for benign prostatic hyperplasia

• Gerald Andriole, MD
• J. Curtis Nickel, MD
• Claus Roehrborn, MD
• Papers: Roehrborn 2002, Roehrborn 2004

There was also a Chinese trial, ARIA108898, which did not include any of the individuals highlighted in this section.

CombAT: Combination of Avodart and Tamsulosin Study Group
Combination therapy with dutasteride and tamsulosin for benign prostatic hyperplasia

• Claus Roehrborn, MD
• Papers: Roehrborn 2008, Barkin 2009, Becher 2009, Chung 2009, Roehrborn 2010, Haillot 2011, Montorsi 2011, Roehrborn 2011a, Roehrborn 2011b, Roehrborn 2012, Oelke 2014, Roehrborn 2014

Dutasteride Alopecia Research Team
ARIA2004: Dutasteride vs. finasteride for male pattern hair loss

• Elise Olsen, MD
• Vera Price, MD
• Roger Rittmaster, MD (GSK)
• Janet Roberts, MD
• Dow Stough, MD
• David Whiting, MD
• Paper: Olsen 2006

EPICS: Enlarged Prostate International Comparator Study
Finasteride vs. dutasteride for benign prostatic hyperplasia

• J. Curtis Nickel, MD
• Roger Rittmaster, MD (GSK)
• Paper: Nickel 2011

REDEEM: Reduction by Dutasteride of Clinical Progression Events in Expectant Management Study Group
Assess whether dutasteride decreases the rate of prostate cancer progression in men with low-risk disease

• Roger Rittmaster, MD
• Papers: Fleshner 2007, Fleshner 2012

REDUCE: Reduction by Dutasteride of Prostate Cancer Events Study Group
Determine whether dutasteride reduces the risk of prostate cancer among men at increased risk

• Gerald Andriole, MD
• Roger Rittmaster, MD (GSK)
• Paper: Andriole 2010